Literature DB >> 23273994

Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer.

Cullen M Taniguchi1, James D Murphy, Neville Eclov, Todd F Atwood, Kayla N Kielar, Claudia Christman-Skieller, Ed Mok, Lei Xing, Albert C Koong, Daniel T Chang.   

Abstract

PURPOSE: To determine how the respiratory phase impacts dose to normal organs during stereotactic body radiation therapy (SBRT) for pancreatic cancer. METHODS AND MATERIALS: Eighteen consecutive patients with locally advanced, unresectable pancreatic adenocarcinoma treated with SBRT were included in this study. On the treatment planning 4-dimensional computed tomography (CT) scan, the planning target volume (PTV), defined as the gross tumor volume plus 3-mm margin, the duodenum, and the stomach were contoured on the end-expiration (CTexp) and end-inspiration (CTinsp) phases for each patient. A separate treatment plan was constructed for both phases with the dose prescription of 33 Gy in 5 fractions with 95% coverage of the PTV by the 100% isodose line. The dose-volume histogram (DVH) endpoints, volume of duodenum that received 20 Gy (V20), V25, and V30 and maximum dose to 5 cc of contoured organ (D5cc), D1cc, and D0.1cc, were evaluated.
RESULTS: Dosimetric parameters for the duodenum, including V25, V30, D1cc, and D0.1cc improved by planning on the CTexp compared to those on the CTinsp. There was a statistically significant overlap of the PTV with the duodenum but not the stomach during the CTinsp compared to the CTexp (0.38 ± 0.17 cc vs 0.01 ± 0.01 cc, P=.048). A larger expansion of the PTV, in accordance with a Danish phase 2 trial, showed even more overlapping volume of duodenum on the CTinsp compared to that on the CTexp (5.5 ± 0.9 cc vs 3.0 ± 0.8 cc, P=.0003) but no statistical difference for any stomach dosimetric DVH parameter.
CONCLUSIONS: Dose to the duodenum was higher when treating on the inspiratory than on the expiratory phase. These data suggest that expiratory gating may be preferable to inspiratory breath-hold and free breathing strategies for minimizing risk of toxicity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23273994     DOI: 10.1016/j.ijrobp.2012.07.2366

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.

Authors:  Vivek Verma; Audrey J Lazenby; Dandan Zheng; Abhijeet R Bhirud; Quan P Ly; Chandrakanth Are; Aaron R Sasson; Chi Lin
Journal:  Radiother Oncol       Date:  2017-01-12       Impact factor: 6.280

2.  Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: A review from NRG oncology.

Authors:  Edward D Brandner; Indrin J Chetty; Tawfik G Giaddui; Ying Xiao; M Saiful Huq
Journal:  Med Phys       Date:  2017-04-20       Impact factor: 4.071

Review 3.  Motion management in gastrointestinal cancers.

Authors:  Hassan Abbas; Bryan Chang; Zhe Jay Chen
Journal:  J Gastrointest Oncol       Date:  2014-06

Review 4.  Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Authors:  Samuel K Kim; Cheng-Chia Wu; David P Horowitz
Journal:  J Gastrointest Oncol       Date:  2016-06

5.  Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy.

Authors:  Guangyin Wu; Vivek Verma; Matthias F Haefner; Sicong Li; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2017-08

6.  Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific α/β-Values for Patients with Non-Resectable Pancreatic Cancer.

Authors:  Constantin Dreher; Christian Scholz; Mira Pommer; Stephan Brons; Hannah Prokesch; Swantje Ecker; Jürgen Debus; Oliver Jäkel; Stephanie E Combs; Daniel Habermehl
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

Review 7.  A current perspective on stereotactic body radiation therapy for pancreatic cancer.

Authors:  Julian C Hong; Brian G Czito; Christopher G Willett; Manisha Palta
Journal:  Onco Targets Ther       Date:  2016-10-31       Impact factor: 4.147

Review 8.  Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?

Authors:  Constantin Dreher; Daniel Habermehl; Oliver Jäkel; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2017-12-27       Impact factor: 3.481

9.  Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.

Authors:  Konstantina Karava; Stefanie Ehrbar; Oliver Riesterer; Johannes Roesch; Stefan Glatz; Stephan Klöck; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2017-11-09       Impact factor: 3.481

10.  Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer.

Authors:  Constantin Dreher; Daniel Habermehl; Swantje Ecker; Stephan Brons; Rami El-Shafie; Oliver Jäkel; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2015-11-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.